

Parkinson's Disease Treatment Market Size, Share and Growth Outlook 2026: By Drug Class, By Administration Route, By Distribution Channel, By Patient Care Facility, Companies to 2034

<https://marketpublishers.com/r/PA107FF9788FEN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: PA107FF9788FEN

Abstracts

The global Parkinson's Disease Treatment Market size is forecast to increase from \$6.34 Billion in 2026 to \$10.37 Billion in 2034 at a CAGR of 6.34% between 2026 and 2034.

The Parkinson's Disease Treatment market report provides detailed analysis and outlook of Parkinson's Disease Treatment segments including By Drug Class (Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Others), By Administration Route (Oral, Injection, Transdermal), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Patient Care Facility (Hospitals, Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Parkinson's Disease Treatment Industry Overview

Disease-Modifying and Regenerative Therapies Are Reshaping Parkinson's Disease Treatment

The Parkinson's disease treatment industry is entering a transformative phase as research shifts beyond symptomatic management toward therapies that slow disease progression, restore neuronal function, and improve long-term patient outcomes. Advances in neuroprotective drugs, regenerative medicine, precision biologics, and non-invasive interventions are expanding the therapeutic landscape for patients across

different stages of disease progression. Pharmaceutical companies, biotechnology developers, and research organizations are increasingly prioritizing treatments that target the underlying neurodegenerative process rather than solely addressing motor symptoms, reflecting a significant evolution in Parkinson's disease management.

Clinical Development Is Accelerating Disease-Modifying Therapies

A major industry trend is the advancement of therapies designed to alter the natural progression of Parkinson's disease. Cure Parkinson's has highlighted the importance of multiple late-stage clinical trials expected to generate key results, including the Phase 3 ASPro-PD study evaluating Ambroxol as a repurposed therapy and Roche's Phase 3 studies of Prasinezumab targeting alpha-synuclein pathology. These clinical programs demonstrate the industry's transition toward disease-modifying approaches that seek to slow or prevent neurodegeneration rather than temporarily masking symptoms, while improving scientific understanding of Parkinson's disease biology.

Regenerative Medicine and Non-Invasive Technologies Expand Treatment Options

The therapeutic landscape is becoming increasingly diversified through the combination of regenerative medicine and advanced device-based interventions. Aspen Neuroscience reported encouraging results from its Phase 1/2a ASPIRO clinical trial evaluating ANPD001, a personalized autologous stem cell therapy designed to replace damaged dopamine-producing neurons and restore neural circuitry. At the same time, regulatory approval for staged bilateral focused ultrasound treatment has expanded access to non-invasive therapy for appropriate patients with advanced Parkinson's disease who have already undergone successful unilateral treatment. Together, these developments illustrate the industry's movement toward highly personalized regenerative therapies alongside minimally invasive alternatives to conventional surgical procedures such as deep brain stimulation.

Precision Medicine Is Defining the Future of Parkinson's Care

The Parkinson's disease treatment market is increasingly integrating molecular research, regenerative technologies, and advanced therapeutic platforms to deliver individualized patient care. Developers are investing in biologics, cell therapies, targeted neuroprotective agents, and image-guided interventions that address multiple mechanisms of disease progression. This convergence of pharmaceutical innovation, regenerative medicine, and non-invasive therapeutic technologies is creating a more

comprehensive treatment ecosystem capable of improving long-term neurological function while expanding therapeutic choices for patients with complex Parkinson's disease.

Parkinson's Disease Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Parkinson's Disease Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GSK plc (GlaxoSmithKline), H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals, Inc., Cerevel Therapeutics, UCB S.A.. The Parkinson's Disease Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Parkinson's Disease Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Parkinson's Disease Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Parkinson's Disease Treatment companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Parkinson's Disease Treatment markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and

long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Parkinson's Disease Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Parkinson's Disease Treatment industry include- AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GSK plc (GlaxoSmithKline), H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals, Inc., Cerevel Therapeutics, UCB S.A.. The Parkinson's Disease Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Parkinson's Disease Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Parkinson's Disease Treatment market remains one of the strongest-performing segments in the country.

The US Parkinson's Disease Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Parkinson's Disease Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across

Parkinson's Disease Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Parkinson's Disease Treatment markets

Canada's strong Parkinson's Disease Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Parkinson's Disease Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Parkinson's Disease Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Parkinson's Disease Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Parkinson's Disease Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Parkinson's Disease Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Parkinson's Disease Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Parkinson's Disease Treatment sales through 2034

France Parkinson's Disease Treatment companies are emphasizing on opportunities

for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Parkinson's Disease Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Parkinson's Disease Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Parkinson's Disease Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Parkinson's Disease Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Parkinson's Disease Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Parkinson's Disease Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Parkinson's Disease Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Parkinson's Disease Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Parkinson's Disease Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Parkinson's Disease Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to

account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Parkinson's Disease Treatment Market Segmentation

By Drug Class

Carbidopa-Levodopa

Dopamine Agonists

MAO-B Inhibitors

COMT Inhibitors

Anticholinergics

Others

By Administration Route

Oral

Injection

Transdermal

By Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

By Patient Care Facility

Hospitals

Clinics

Leading Companies in Parkinson's Disease Treatment Industry (2026)

AbbVie Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Merck & Co., Inc.

GSK plc (GlaxoSmithKline)

H. Lundbeck A/S

Amneal Pharmaceuticals LLC

Supernus Pharmaceuticals, Inc.

Cerevel Therapeutics

UCB S.A.

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Parkinson's Disease Treatment Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Parkinson's Disease Treatment Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL PARKINSON'S DISEASE TREATMENT MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Parkinson's Disease Treatment Markets in 2026
- 3.2. Global Historic and Forecast Parkinson's Disease Treatment Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Parkinson's Disease Treatment Market Driving Forces and Their Impact on

Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Parkinson's Disease Treatment Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Parkinson's Disease Treatment Value Chain

CHAPTER 4- PARKINSON'S DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Parkinson's Disease Treatment Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- PARKINSON'S DISEASE TREATMENT MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Drug Class

Carbidopa-Levodopa
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Anticholinergics
Others
By Administration Route
Oral
Injection
Transdermal
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Patient Care Facility
Hospitals
Clinics

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

- 6.1. Base Case Scenario
 - 6.1.1. Definitions and Insights
 - 6.1.2. Market Size Outlook to 2034
- 6.2. Low Growth Case Scenario
 - 6.2.1. Definitions and Insights
 - 6.2.2. Market Size Outlook to 2034
- 6.3. High Growth Case Scenario
 - 6.3.1. Definitions and Insights
 - 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA PARKINSON'S DISEASE TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Parkinson's Disease Treatment Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Parkinson's Disease Treatment Market Trends and Growth Opportunities to 2034
- 7.5. North America Parkinson's Disease Treatment Market Size Outlook by Type

- 7.6. North America Parkinson's Disease Treatment Market Size Outlook by Application
- 7.7. North America Parkinson's Disease Treatment Market Size Outlook by Country
- 7.8. United States
 - 7.8.1. Key Statistics
 - 7.8.2. The US Parkinson's Disease Treatment Market Size Outlook, 2021- 2034
 - 7.8.3. Key Market Drivers and Industry Developments in the US Parkinson's Disease Treatment Companies
- 7.9. Canada
 - 7.9.1. Key Statistics
 - 7.9.2. Canada Parkinson's Disease Treatment Market Size Outlook, 2021- 2034
 - 7.9.3. Key Market Drivers and Industry Developments in Canada Parkinson's Disease Treatment Companies
- 7.10. Mexico
 - 7.10.1. Key Statistics
 - 7.10.2. Mexico Parkinson's Disease Treatment Market Size Outlook, 2021- 2034
 - 7.10.3. Key Market Drivers and Industry Developments in Mexico Parkinson's Disease Treatment Companies

CHAPTER 8- EUROPE PARKINSON'S DISEASE TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK

- 8.1. Europe Parkinson's Disease Treatment Market Overview, 2026
- 8.2. Leading Companies Operating in Europe
- 8.3. Key Industry Statistics, 2026
- 8.4. Europe Parkinson's Disease Treatment Market Trends and Growth Opportunities to 2034
- 8.5. Europe Parkinson's Disease Treatment Market Size Outlook by Type
- 8.6. Europe Parkinson's Disease Treatment Market Size Outlook by Application
- 8.7. Europe Parkinson's Disease Treatment Market Size Outlook by Country
- 8.8. Germany
 - 8.8.1. Key Statistics
 - 8.8.2. Germany Parkinson's Disease Treatment Market Size Outlook, 2021- 2034
 - 8.8.3. Key Market Drivers and Industry Developments in Germany Parkinson's Disease Treatment Companies
- 8.9. France
 - 8.9.1. Key Statistics
 - 8.9.2. France Parkinson's Disease Treatment Market Size Outlook, 2021- 2034
 - 8.9.3. Key Market Drivers and Industry Developments in France Parkinson's Disease Treatment Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Parkinson's Disease Treatment Market Size Outlook, 2021-2034

8.10.3. Key Market Drivers and Industry Developments in the UK Parkinson's Disease Treatment Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Parkinson's Disease Treatment Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Parkinson's Disease Treatment Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Parkinson's Disease Treatment Market Size Outlook, 2021-2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Parkinson's Disease Treatment Companies

CHAPTER 9- ASIA PACIFIC PARKINSON'S DISEASE TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Parkinson's Disease Treatment Market Overview, 2026

9.2. Leading Companies Operating in Asia Pacific

9.3. Key Industry Statistics, 2026

9.4. Asia Pacific Parkinson's Disease Treatment Market Trends and Growth Opportunities to 2034

9.5. Asia Pacific Parkinson's Disease Treatment Market Size Outlook by Type

9.6. Asia Pacific Parkinson's Disease Treatment Market Size Outlook by Application

9.7. Asia Pacific Parkinson's Disease Treatment Market Size Outlook by Country

9.8. China

9.8.1. Key Statistics

9.8.2. China Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.8.3. Key Market Drivers and Industry Developments in China Parkinson's Disease Treatment Companies

9.9. Japan

9.9.1. Key Statistics

9.9.2. Japan Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Parkinson's Disease Treatment Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Parkinson's Disease Treatment Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Parkinson's Disease Treatment Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Parkinson's Disease Treatment Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Parkinson's Disease Treatment Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA PARKINSON'S DISEASE TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Parkinson's Disease Treatment Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Parkinson's Disease Treatment Market Trends and Growth Opportunities to 2034

10.5. South and Central America Parkinson's Disease Treatment Market Size Outlook by Type

10.6. South and Central America Parkinson's Disease Treatment Market Size Outlook

by Application

10.7. South and Central America Parkinson's Disease Treatment Market Size Outlook
by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Parkinson's Disease
Treatment Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Parkinson's
Disease Treatment Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Parkinson's Disease Treatment Market Size Outlook,
2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America
Parkinson's Disease Treatment Companies

CHAPTER 11- MIDDLE EAST AND AFRICA PARKINSON'S DISEASE TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Parkinson's Disease Treatment Market Overview, 2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Parkinson's Disease Treatment Market Trends and
Growth Opportunities to 2034

11.5. Middle East and Africa Parkinson's Disease Treatment Market Size Outlook by
Type

11.6. Middle East and Africa Parkinson's Disease Treatment Market Size Outlook by
Application

11.7. Middle East and Africa Parkinson's Disease Treatment Market Size Outlook by
Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Parkinson's
Disease Treatment Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Parkinson's Disease Treatment Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Parkinson's Disease Treatment Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Parkinson's Disease Treatment Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Parkinson's Disease Treatment Industry

AbbVie Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Merck & Co., Inc.

GSK plc (GlaxoSmithKline)

H. Lundbeck A/S

Amneal Pharmaceuticals LLC

Supernus Pharmaceuticals, Inc.

Cerevel Therapeutics

UCB S.A.

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Parkinson's Disease Treatment Market Size, Share and Growth Outlook 2026: By Drug Class, By Administration Route, By Distribution Channel, By Patient Care Facility, Companies to 2034

Product link: <https://marketpublishers.com/r/PA107FF9788FEN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA107FF9788FEN.html>